Form 4 holding
Director
Nuvalent, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 1,447,267
- Estimated value
- $127,359,496
- Report date
- 11 Dec 2024
- Price
- $88.00
- Ownership
- Indirect
Andrew A. F. Hack
Insider Reports History
- Reporting-owner location
- Cambridge, MA
- Latest reporting-owner signature
-
/s/ Andrew Hack
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Andrew A. F. Hack
Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Common Stock
- Shares / value
- 915,000
- Estimated value
- $13,725,000
- Report date
- 08 Aug 2023
- Price
- $15.00
- Ownership
- Indirect
Form 4 holding
Director
Nuvalent, Inc.
- Security class
- Class A Common Stock
- Shares / value
- 2,499
- Estimated value
- $219,912
- Report date
- 11 Dec 2024
- Price
- $88.00
- Ownership
- Direct
Form 4 holding
Director
DYNAVAX TECHNOLOGIES CORP
- Security class
- Common Stock
- Shares / value
- 10,714
- Estimated value
- $160,710
- Report date
- 08 Aug 2023
- Price
- $15.00
- Ownership
- Direct
Form 4 holding
Director
Mersana Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 06 Jan 2026
- Price
- $28.14
- Ownership
- Direct
Form 4 holding
Director
Mersana Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 06 Jan 2026
- Price
- $28.14
- Ownership
- Indirect
Form 4 holding
Director
Nuvalent, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 3,789
- Estimated value
- Report date
- 12 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
Form 4 holding
Director
Mersana Therapeutics, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 0
- Estimated value
- Report date
- 06 Jan 2026
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Andrew A. F. Hack
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 06 Jan 2026
- Transactions
- 13
- Transaction value
- $0
- Accepted by SEC
- 06 Jan 2026, 18:32
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 12 Jun 2025
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 13 Jun 2025, 17:10
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 11 Dec 2024
- Transactions
- 1
- Transaction value
- -$110,000,000
- Accepted by SEC
- 13 Dec 2024, 16:30
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 12 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 16:53
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 11 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2024, 17:31
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 27 Mar 2024
- Transactions
- 2
- Transaction value
- -$64,035,959
- Accepted by SEC
- 29 Mar 2024, 17:15
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 08 Aug 2023
- Transactions
- 1
- Transaction value
- -$21,585,000
- Accepted by SEC
- 10 Aug 2023, 16:31
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 15 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2023, 17:08
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 14 Jun 2023
- Transactions
- 1
- Transaction value
- -$6,340,000
- Accepted by SEC
- 16 Jun 2023, 16:30
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 08 Jun 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 12 Jun 2023, 17:25
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 26 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 31 May 2023, 17:43
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 18 May 2023
- Transactions
- 1
- Transaction value
- -$10,550,000
- Accepted by SEC
- 19 May 2023, 16:30
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 06 Dec 2022
- Transactions
- 1
- Transaction value
- -$17,400,000
- Accepted by SEC
- 08 Dec 2022, 15:41
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 03 Nov 2022
- Transactions
- 1
- Transaction value
- +$4,999,976
- Accepted by SEC
- 03 Nov 2022, 16:15
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 15 Aug 2022
- Transactions
- 1
- Transaction value
- -$44,040,000
- Accepted by SEC
- 17 Aug 2022, 17:17
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 16 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 17 Jun 2022, 17:13
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 09 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 10 Jun 2022, 17:25
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 31 May 2022
- Transactions
- 2
- Transaction value
- +$311,958
- Accepted by SEC
- 02 Jun 2022, 18:17
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 26 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 27 May 2022, 17:29
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 24 May 2022
- Transactions
- 3
- Transaction value
- +$854,175
- Accepted by SEC
- 26 May 2022, 18:02
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 19 May 2022
- Transactions
- 3
- Transaction value
- +$746,437
- Accepted by SEC
- 23 May 2022, 17:49
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 16 May 2022
- Transactions
- 3
- Transaction value
- +$1,137,660
- Accepted by SEC
- 18 May 2022, 18:19
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 13 Apr 2022
- Transactions
- 1
- Transaction value
- +$2,500,000
- Accepted by SEC
- 14 Apr 2022, 16:59
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 12 Apr 2022
- Transactions
- 1
- Transaction value
- +$2,499,880
- Accepted by SEC
- 13 Apr 2022, 18:27
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 07 Feb 2022
- Transactions
- 1
- Transaction value
- +$5,022,724
- Accepted by SEC
- 08 Feb 2022, 16:04
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 03 Jan 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 05 Jan 2022, 17:47
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 30 Dec 2021
- Transactions
- 1
- Transaction value
- +$5,012,250
- Accepted by SEC
- 04 Jan 2022, 17:16
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 29 Dec 2021
- Transactions
- 1
- Transaction value
- +$5,031,250
- Accepted by SEC
- 03 Jan 2022, 17:28
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 27 Aug 2021
- Transactions
- 3
- Transaction value
- -$32,440,000
- Accepted by SEC
- 27 Aug 2021, 20:07
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 09 Aug 2021
- Transactions
- 3
- Transaction value
- -$24,300,000
- Accepted by SEC
- 11 Aug 2021, 18:26
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 02 Aug 2021
- Transactions
- 3
- Transaction value
- +$12,495,000
- Accepted by SEC
- 04 Aug 2021, 17:12
- Role
- Director
- Next action
- Open filing details
4
NUVL
Nuvalent, Inc.
- Report period
- 28 Jul 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 30 Jul 2021, 17:57
- Role
- Director
- Next action
- Open filing details
3
NUVL
Nuvalent, Inc.
- Report period
- 28 Jul 2021
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 28 Jul 2021, 21:29
- Role
- Director
- Next action
- Open filing details
4
MRSN
Mersana Therapeutics, Inc.
- Report period
- 11 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 15 Jun 2021, 18:35
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 10 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Jun 2021, 17:23
- Role
- Director
- Next action
- Open filing details
4
DVAX
DYNAVAX TECHNOLOGIES CORP
- Report period
- 28 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 02 Jun 2021, 19:00
- Role
- Director
- Next action
- Open filing details